Get the Stockscreener App
283.25
0.59%
2.4209
Praxis Precision Medicines Inc stock is traded at $283.25, with a volume of 26,348.
It is up +0.59% in the last 24 hours and up +5.10% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$280.83
Open:
$282.95
24h Volume:
26,348
Relative Volume:
0.03
Market Cap:
$7.86B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-30.89
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-3.46%
1M Performance:
+5.10%
6M Performance:
+427.05%
1Y Performance:
+329.07%
1-Day Range:
$279.04
$285.00
1-Week Range:
$266.93
$305.21
52-Week Range:
$26.70
$317.72
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
283.40 | 7.79B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.23 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.53 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
806.85 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
367.69 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
343.01 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy - PharmiWeb.com
Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? - Yahoo Finance
Buyout Rumor: Can Praxis Precision Medicines Inc deliver consistent dividendsJuly 2025 Trends & Smart Money Movement Alerts - baoquankhu1.vn
Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy - Quiver Quantitative
Praxis Precision Medicines Appoints Orrin Devinsky as Head of Clinical Strategy - marketscreener.com
US Biotech Share Sales Deliver Biggest First Week Since 2021 - Bloomberg.com
Praxis Precision Medicines plans two NDA submissions by mid-February - Investing.com Nigeria
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress - Investing News Network
PRAX: Wedbush Raises Price Target Despite "Underperform" Rating - GuruFocus
Praxis Precision Medicines (PRAX) Sets Ambitious Targets for 202 - GuruFocus
Two new brain disorder drugs head to FDA as Praxis nears key 2026 data - Stock Titan
Needham analyst keeps a buy rating on Praxis Precision Medicines, Inc. (PRAX) - MSN
Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) - Insider Monkey
20 Best Performing Stocks in 2025 - Insider Monkey
Will Praxis Precision Medicines Inc. stock see PE expansionPerformance Line Overview & quick comparison of popular models - ulpravda.ru
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision (PRAX) Announces Key Leadership Changes - GuruFocus
Praxis Precision Medicines appoints new board members, promotes executives By Investing.com - Investing.com India
Praxis Precision Medicines appoints new board members, promotes executives - Investing.com
Praxis Precision Medicines Announces Key Management Appointments - TradingView — Track All Markets
Praxis Precision Medicines Announces New Board Appointments and Executive Promotions to Drive Growth and Commercial Readiness - Quiver Quantitative
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Chartmill
Will Praxis Precision Medicines Inc. stock reach all time highs in 2025 - ulpravda.ru
How strong is Praxis Precision Medicines Inc. stock balance sheet2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
Will Praxis Precision Medicines Inc. stock benefit from commodity pricesJuly 2025 Volume & Real-Time Market Sentiment Alerts - ulpravda.ru
S P Trends: Is Praxis Precision Medicines Inc. stock a smart buy before Fed meeting2025 Technical Patterns & Expert Approved Trade Ideas - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a smart buy before Fed meetingJuly 2025 Selloffs & Real-Time Stock Movement Alerts - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a buy in volatile marketsJuly 2025 EndofMonth & Capital Efficient Trade Techniques - ulpravda.ru
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
PRAX Stock Surge: Time to Buy? - StocksToTrade
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Praxis Precision Medicines Announces Major Underwritten Equity Offering - TipRanks
Praxis Precision Medicines Announces Underwritten Offering - TradingView — Track All Markets
Praxis Precision Medicines (PRAX) Valuation Check After A Strong 90 Day Share Price Run - Yahoo Finance
Praxis Precision stock rises as $575 million share sale clears at $260 - TechStock²
Praxis Precision Medicines edges down after $575 mln stock sale - TradingView — Track All Markets
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Biotech targeting CNS disorders lines up $575M stock sale - Stock Titan
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - Sahm
Praxis Precision Prices $575 Mln Public Offering At $260/shr - Nasdaq
Praxis Precision (PRAX) Announces Public Offering of Stock and W - GuruFocus
Praxis Precision Medicines (PRAX) Announces $575M Public Offerin - GuruFocus
Praxis Precision prices $575M stock offering at $260 - MSN
Praxis Precision Medicines prices public offering at $260 per share By Investing.com - Investing.com Australia
Praxis Precision Medicines prices public offering at $260 per share - Investing.com
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - Yahoo Finance
Praxis Precision Medicines Announces Pricing of Public Offering of Common Stock at $260 Per Share - Quiver Quantitative
Los Angeles Daily NewsPraxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - FinancialContent
Praxis Precision Medicines reports preliminary $925 million in cash and securities - Investing.com Australia
Praxis Precision Medicines announces proposed public offering By Investing.com - Investing.com Nigeria
Praxis Precision Medicines reports preliminary $925 million in cash and securities By Investing.com - Investing.com South Africa
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.12%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):